Mark Pepys is a physician and immunologist whose work on blood proteins has elucidated mechanisms of disease, identified new targets for treatment and led to improved diagnosis and treatments.
He invented a unique, non-invasive scan for diagnosis and monitoring of patients with amyloidosis, a fatal disease caused by accumulation of abnormal protein fibres in the tissues. His work has greatly improved understanding, management and outcome of the disease, and he founded the world-leading , which serves patients from the United Kingdom and many from abroad.
Mark has also designed new therapeutic approaches for amyloidosis and Alzheimer’s disease. His treatment for amyloidosis is being developed by GlaxoSmithKline in collaboration with the Wolfson Drug Discovery Unit at UCL, and its clinical trial is providing positive results. The first clinical trial of his potential drug for Alzheimer’s disease, supported by the UCL/UCLH Biomedical Research Centre, will start in 2016.
Professional position
- Director of Wolfson Drug Discovery Unit, Department of Medicine, University College London (UCL)
- Professorial Clinical Research Associate, Department of Medicine, University College London (UCL)
- Honorary Fellow, Trinity College, University of Cambridge
- Emeritus Professor of Medicine, University College London (UCL)
Subject groups
-
Other
Other interests
-
Health and Human Sciences
Medicine, clinical studies
Awards
-
Royal Society GlaxoSmithKline Prize and Lecture
For his excellent work as a clinical scientist who has identified specific proteins as new therapeutic targets and developed novel drugs with potential use in amyloidosis, Alzheimer's disease and cardiovascular disease.
